NCT00054548 2013-05-16
Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
Clinical Trials
8 trialsNCT00004862 2013-02-01
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00017251 2013-01-24
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00039481 2013-01-17
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00636545 2012-04-06
Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors
Genta Incorporated
Phase 1 Completed
NCT00409383 2011-11-07
Abraxane and Temodar Plus Genasense in Advanced Melanoma
Genta Incorporated
Phase 1 Unknown
NCT00070083 2009-04-07
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00543231 2007-10-12
A Phase I Study of G3139 Subcutaneous in Solid Tumors
Genta Incorporated
Phase 1 Completed